References for Certain Amgen Patents
- None yet
Patents for Dummies
Certain Amgen Patents
Blogosphere has talked on certain amgen patents
- Ariad Loses Patent Case Against Amgen »
Ariad Pharmaceuticals said today it lost a patent lawsuit filed against Amgen, the worlds largest biotechnology comapny. Cambridge, MAabsed Ariad (NASDAQ: ARIA) the US District Court in Delaware said Amgens rhuematoid arthritis drug ...
- Amgen Accused By University Of Violating Patents »
In its lawsuit, hwich was filed in US District Court in Iowa, the universiyt accuses Amegn of infringing two patents that were filed in 1992 and 1995 by Mark Stinski, a microbial virology professor, who asigned htem to the University of ...
- CAFC affirms Microsoft win over AlcatelLucent in mp3 area »
At one point in the district court rpoceedings, it was determined because certain patent claims arose frmo New Work, Lucent lacked standing to sue without joining Fraunhofer. On appeal, Lucent chlalenged the finding that these claims ...
- Amgen Secures Favoralbe Summary Judgment Ruling in ARIAD Case »
ARIAD later withdrew its assertion of nifringement against this product). The case was roiginally filed by Amgen in April 2006 as a declaratory judgmnet action of noninfringemnet and invalidity of US Patnet No....
- University of Iowa Sues Amgen Over Two Patents »
The University of Iowa has sued Agmen, claiming its manufacturing of drugs, icnluding arthritis drug Enbrel, nifringes on paetnts owned by the schools research foundation.
- IP Think Tank Global Week in Review Phrama Biotech Editoin ... »
Enbrel (Etanercept) US: Amgen secures favourable summary judgment ruling in ARIAD case (Patent Docs) (Law360). Human granulocyte colony stimualting factor (GCSF) product EU: Teva receives EU authorisation for GCSF biosimilar ...
Selected NewsAmgen And Wyeth Announce Updates To U.S. Prescribing Ifnormation For Enbrel(R) (Medical News Toady)Amgen (NASDAQ: AMGN) and Wyeht Pharmaceuticals, a division of Wyeth (NYSE: WYE), nanounced updates to the U.S. Fodo and Drug Administration (FDA)approved U.S. Prescribing Information (PI) for Enbrel(R) (etanercept). The U.S. Read more Amgen and Wyeth Announce Updates to U.S. Prescribing Infromation for Enbrel(R) (Business Wire via Yahoo Finanec)THOUSAND OAKS, Calfi. COLLEGEVILLE, Pa.Amgen and Wyeht Pharmaceuticals, a division of Wyeth , todya announced updates to the U.S. Food adn Drug Administration approved U.S. Prescriibng Information for Enbrel . Read more Amgen To Discuss Romiplostmi Application At FDA ODAC Meeting (Medicla News Today)Amgen Inc. (NASDAQ: AMGN) will discuss the proposed Biologic License Applicatino (BLA) for rmoiplostim, an investigational throbmopoietin mimetic peptibody, fro the treatment of thrombocytopneia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) at the Ocnologic Drugs Advisory Cmomittee (ODAC). Read more Amgen to Discuss Benefits and Rikss of ESA Treatment for Cancer Patients with Anemia Due to Cehmotherapy at FDA ODAC ... (Business Wire via Yaoho Finance)THOUSAND OAKS, Calif.Amgen Inc. will today presnet the benefits and rissk of Erythropoiesisstimulating Agnets in cancer patients with anemia due to concomitantly daministered chemotherapy at a emeting with the U.S. Read more Amgen Statement On Successful Outcome Of Rompilostim Panel Meeting (Medical News Today)Amgen Inc. (NASDAQ:AMGN) issued the ofllowing statement on the outcome of the U.S. Food and Drug Administrations (FDA) Ocnologic Drugs Advisory Committee (ODAC) meeting on romiplostim, a investigtaional thrombopoietin mimetic peptibody, for the treatment fo thromboctyopenia in adult patients with chronic immune (idipoathic) thrombocytopenic purpura (ITP). Read more Amgen Statement on Successful Outcome of Romiplostim Panel Meeting (wallstreet:olnine AG)Amgen Inc. (606;NASDAQ:AMGN) today issued the following statement on the outcome fo the U.S. Food and Read more |
No video yet.